ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 18

The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review

Jenny Shu1, Panos Lambiris2 and Claire Bombardier3, 1Department of Rheumatology, University of Toronto, Toronto, ON, Canada, 2University Health Network, Toronto, ON, Canada, 3Toronto General Hospital Research Institute, Toronto, ON, Canada

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Biologic agents, randomized trials, rheumatic disease and work, Work Disability

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Epidemiology and Public Health - Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  Biological therapy has been shown to have a positive effect on work outcomes, such as work participation and/or work disability in patients with chronic inflammatory rheumatic diseases. However, work outcomes are often dependent on contextual factors. Our objective is to specifically identify both the disease-related and contextual factors that impact work outcomes in patients with chronic inflammatory arthritis treated with biologics.

Methods: A systematic literature search was conducted using the Medline, Embase, two Cochrane, and CINAHL databases as well as hand searches from conference archives and clinicaltrials.gov to identify publications relating to chronic inflammatory rheumatic diseases (specifically rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), systemic erythematous lupus (SLE), Sjogren’s syndrome, or systemic sclerosis (Ssc)) in double-blind, randomized-controlled biological therapy trials with work outcomes as a primary or secondary outcome. Only studies that describe a relationship between either a disease-related or contextual (CoFas) factor and work outcome were included. A critical appraisal of the included studies was performed to determine methodological flaws in the study design and to assess for possible bias.

Results:  Of the 1649 abstracts retrieved, 13 studies met inclusion criteria. The RCT’s included 3 chronic inflammatory diseases (AS= 3, PsA =2, RA = 8). The follow-up period was between 12 weeks to 2 years. Biologics used include etanercept (4 studies), infliximab (3 studies), adalimumab (3 studies), and single studies with golimumab, abatacept, and certolizumab pegol. Despite study heterogeneity, there was an overall positive effect of biological therapy on work outcomes. Disease-related factors which correlated with work outcomes included patient-reported outcomes such as the health assessment questionnaire (HAQ) in 7 studies, fatigue in 3 studies, and pain in 2 studies, as well as specific disease activity and remission markers. Only 6 studies examined contextual factors. Specifically, personal factors such as female gender (4 studies) and older age (4 studies) had a negative impact on work outcomes. Environmental factors that correlated with better work outcomes include non-manual type of jobs, higher baseline number of hours worked, and lower baseline number of sick days.

Conclusion:  Our results show that the positive effect of biological therapy on work outcomes is likely a result of interplay between better disease control as well as favorable patient and work environment contextual factors. Further trials identifying these variables will be important for the evaluation and prediction of work outcomes in RCT’s with biological therapy for patients with chronic inflammatory diseases.


Disclosure: J. Shu, None; P. Lambiris, None; C. Bombardier, None.

To cite this abstract in AMA style:

Shu J, Lambiris P, Bombardier C. The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/the-impact-of-disease-related-and-contextual-factors-on-work-outcomes-in-chronic-inflammatory-arthritis-patients-treated-with-biologics-a-systematic-review/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-impact-of-disease-related-and-contextual-factors-on-work-outcomes-in-chronic-inflammatory-arthritis-patients-treated-with-biologics-a-systematic-review/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology